KORU Medical Systems (KRMD) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Market Cap: $189.7MFounded: 1980HQ: Mahwah, United States

Sector Ranking#83 in Drug Delivery & Formulation

Overview

KORU Medical Systems is a mission-driven company commercializing subcutaneous infusion systems to enable home-based care for chronic therapies, primarily in immunology. A key recent achievement is the FDA clearance of its FreedomEDGE® pump for the administration of UCB's RYSTIGGO® (rozanolixizumab-noli) in generalized myasthenia gravis, validating its strategy of pursuing drug-specific indications. The company leverages a focused commercial team and a 510(k)-cleared platform to target the large and growing market for subcutaneous immunoglobulin (SCIg) and other biologics, aiming to reduce healthcare burdens and improve patient freedom.

ImmunologyNeurology

Technology Platform

The Freedom™ Infusion System platform, comprising the Freedom60 and FreedomEDGE syringe infusion pumps, High-Flo™ safety needle sets, and Precision™ tubing, is engineered for the controlled, portable subcutaneous delivery of high-volume and high-viscosity biologics, enabling home-based therapy.

Funding History

1

IPOUndisclosedUndisclosedApr 4, 2019

Opportunities

The macro shift towards subcutaneous biologics and home-based care presents a substantial growth tailwind.

KORU's validated partnership model, exemplified by the RYSTIGGO® clearance, opens a new channel for predictable, high-margin revenue by becoming the designated delivery device for partnered drugs.

Risk Factors

Revenue is heavily concentrated in the subcutaneous immunoglobulin market, creating vulnerability to reimbursement changes or competitive pressure.

The promising partnership-dependent growth strategy also introduces reliance on the commercial success of collaborators' drug candidates.

Competitive Landscape

KORU competes against traditional IV infusion, simple auto-injectors for low-volume drugs, and other SC pump manufacturers. Its defensible niche is high-volume/viscosity SC delivery, where it holds an established position and is pursuing a differentiated drug-device combination strategy to lock in market share.